Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
41 Leser
Artikel bewerten:
(0)

Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018: Key Vendors are Bristol Myers Squibb, Celgene, Eli Lilly and Co, F. Hoffman La-Roche and GlaxoSmithKline

DUBLIN, Oct. 10, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system.

It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests.

The analysts forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow at a CAGR of 7.03 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market.

The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Market penetration of biologics is expected to dominate the Global NHL Therapeutics market. Rituxan (Rituximab) by Roche got FDA approval in 1997 for the treatment of NHL. It is the first monoclonal antibody developed for the treatment of cancer, and it meets the expected safety and efficacy parameters. Zevalin (Ibritumomab Tiuxetan) by Roche is also a monoclonal antibody radioimmunotherapy treatment meant for relapsed NHL.

According to the report, one of the important drivers is the availability of low-cost biosimilars. Biosimilars offer patient benefit by providing low-cost alternatives to highly priced biologics, which are generally used for the treatment of NHL.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

09. Pipeline Portfolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series

Companies Mentioned:

  • Bristol Myers Squibb
  • Celgene
  • Eli Lilly and Co
  • F. Hoffman La-Roche Ltd.
  • GlaxoSmithKline plc
  • Accredo Health Group Inc.
  • Baxter International Inc.
  • Bayer AG
  • Cephalon Inc.
  • Eisai Pharmaceuticals Inc.
  • Genelabs Technologies Inc.
  • Hospira Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Millenium Pharmaceuticals Inc.
  • Pacira Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Inc.

For more information visit http://www.researchandmarkets.com/research/fv626b/global

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.